[ad_1]
This “Dihydroorotate Dehydrogenase Inhibitor-Pipeline Insight, 2021” Drug pipeline has been added to ResearchAndMarkets.com provide.
This “Dihydroorotate Dehydrogenase Inhibitors-Pipeline Insights 2021” report provides comprehensive insights on more than 10 companies and more than 10 pipeline drugs in the field of dihydroorotate dehydrogenase inhibitors.
It covers an overview of pipeline drugs, including clinical and non-clinical stage products. It also covers treatment evaluations by product type, stage, route of administration, and molecular type. It further highlights the inactive pipeline products in this field.
Highlights of the report
These companies and scholars are working hard to assess the challenges and look for opportunities that may affect the development of dihydroorotate dehydrogenase inhibitors. Therapies under development focus on new methods of dihydroorotate dehydrogenase inhibitors.
Emerging Drugs of Dihydroorotate Dehydrogenase Inhibitor
This part of the Dihydroorotate Dehydrogenase Inhibitor Report provides a detailed analysis of various drugs in different clinical development stages, including III, II, I, preclinical and discovery stages. It also helps to understand the details of clinical trials, expressive pharmacology, agreements and cooperation, as well as the latest news and press releases.
Emerging drugs for dihydroorotate dehydrogenase inhibitors
IMU-838: Immunity
IMU-838 is an investigational drug based on a small molecule oral tablet formulation that can inhibit the enzyme dihydroorotate dehydrogenase (DHODH). IMU-838 is in clinical development for the treatment of relapsing-remitting multiple sclerosis or RRMS, inflammatory bowel disease or IBD, and other chronic inflammation and autoimmune diseases. This…
The full story on Benzinga.com
[ad_2]
Source link
